中国药学会智能药物青年委员。四川省学术与技术带头人后备人选，四川大学“双百人才工程”入选者。Pharmaceutical Science Advances杂志第一届青年编委。

长期在杨胜勇教授领衔的团队中聚焦GPCR动态调控机制与先导化合物发现研究。先后主持国家自然科学基金青年科学基金项目（B类）[原优秀青年科学基金项目]、国家自然科学基金面上项目等国家级项目，以研究骨干身份参加国家自然基金创新研究群体项目、国家重点研发计划、国家“重大新药创制”等项目。

相关成果以第一/通讯作者发表于Nature Medicine、Nature Chemical Biology、PNAS、Journal of Medicinal Chemistry等国际权威期刊。研究成果被诺贝尔化学奖得主Kobilka教授等重点引用和评价。受邀在Chemical Reviews撰写相关进展总结和展望，被评为该刊年度TOP10阅读量文章，并入选ESI高被引论文，在国际上产生了重要影响。所在的杨胜勇教授团队，一直聚焦药物分子设计新方法以及针对重大疾病的原创小分子靶向药物研究。研发的5个1类新药正在开展I-III期临床试验，多个候选药物进入临床前研究。

热烈欢迎对药物分子设计、分子模拟、人工智能、化学生物学、药物化学感兴趣的研究生加入我们团队。

【代表性论著】

1. Xin Yang, Xuehui Wang, Zheng Xu, Chao Wu, Yangli Zhou, Yifei Wang, Guifeng Lin, Kan Li, Ming Wu, Anjie Xia, Jingming Liu, Lin Cheng, Jun Zou, Wei Yan, Zhenhua Shao*, Shengyong Yang*; Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1, Nature Chemical Biology, 2022, 18(8): 831-840.

2. Xin Yang, Pei Zhoua, Siyuan Shena, Qian Hua, Chenyu Tiana, Anjie Xia, Yifei Wang, Zhiqian Yang, Jinshan Nan, Yangli Zhou, Shasha Chen, Xiaowen Tian, Chao Wu, Guifeng Lin, Liting Zhang, Kexin Wang, Tao Zheng, Jun Zou, Wei Yan, Zhenhua Shao*, Shengyong Yang*; Entropy drives the ligand recognition in G protein-coupled receptor subtypes, PNAS, 2024, 121(30): e2401091121.

3. Kang Zhang#; Xin Yang#; Yifei Wang#; Yunfang Yu#; Niu Huang; Gen Li; Xiaokun Li; Joseph C. Wu; Shengyong Yang; Artificial intelligence in drug development, Nature Medicine, 2025, 31(1): 45-59.

4. Siyuan Shen#, Chao Wu#, Guifeng Lin#, Xin Yang#, Yangli Zhou#, Chang Zhao, Zhuang Miao, Xiaowen Tian, Kexin Wang, Zhiqian Yang, Zhiyu Liu, Nihong Guo, Yueshan Li, Anjie Xia, Pei Zhou, Jingming Liu, Wei Yan, Bowen Ke*, Shengyong Yang*, and Zhenhua Shao*; Structure-based identification of a G protein–biased allosteric modulator of cannabinoid receptor CB1, PNAS, 2024, 121(24):e2321532121.

5. Jinshan Nan, Jingming Liu, Guifeng Lin, Shanshan Zhang, Anjie Xia, Pei Zhou, Yangli Zhou, Jiahao Zhang, Jinlong Zhao, Shiyu Zhang, Chong Huang, Yifei Wang, Qian Hu, Junxian Chen, Mingli Xiang, Xin Yang*, Shengyong Yang*; Discovery of 4-(1,2,4-Oxadiazol-5-yl)azepan-2-one Derivatives as a New Class of Cannabinoid Type 2 Receptor Agonists for the Treatment of Inflammatory Pain, Journal of Medicinal Chemistry, 2023, 66(5): 3460-3483.